Study S000345

A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00765817
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 261
Start: 2008-10
Primary completion: 2010-01
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:placebo; DRUG:exenatide
Results posted: TRUE

Registered primary outcomes

Change in Glycosylated Hemoglobin (HbA1c) [baseline and 30 weeks]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0040990	Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes Controlled Trial	2015	Randomized trial		cites ClinicalTrials.gov:NCT00765817
R0026389	Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. Buse JB, Current medical research and opinion	2014	Randomized trial	PMID 24621255 DOI	cites ClinicalTrials.gov:NCT00765817; registry reference DERIVED:24621255
R0018919	Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Pencek R, Postgraduate medicine	2012	Randomized trial	PMID 22913891 DOI	cites ClinicalTrials.gov:NCT00765817; registry reference DERIVED:22913891
R0026563	Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Rosenstock J, Diabetes care	2012	Other	PMID 22432107 DOI	cites ClinicalTrials.gov:NCT00765817; registry reference DERIVED:22432107
R0027069	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Buse JB, Annals of internal medicine	2011	Randomized trial	PMID 21138825 DOI	cites ClinicalTrials.gov:NCT00765817; registry reference DERIVED:21138825